SEC Company Response from Outlook Therapeutics, (OTLK) — May 5, 2016

Outlook Therapeutics, Inc.
Date: May 5, 2016 · CIK: 0001649989 · Accession: 0001571049-16-014898

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-209011

Date

May 5, 2016

Author

JEFFERIES LLC

Form

CORRESP

Company

Outlook Therapeutics, Inc.

Letter

Re: Oncobiologics, Inc. Registration Statement No. 333-209011

May 5, 2016

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, D.C. 20549

Attention: Suzanne Hayes

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on May 4, 2016, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for May 5, 2015 at 4:00 p.m. Eastern time in accordance with Rule 461 of the Securities Act of 1933, as amended.

As representatives of the several underwriters of the proposed public offering, we hereby respectfully withdraw our request for acceleration of the effectiveness of the above-referenced Registration Statement set forth in our May 4, 2016 letter.

Very truly yours,
JEFFERIES LLC

Show Raw Text

CORRESP
1
filename1.htm

May 5, 2016

Via EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, D.C. 20549

Attention: Suzanne Hayes

  Re:     Oncobiologics, Inc. Registration
Statement No. 333-209011

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence
via EDGAR on May 4, 2016, in which we requested the acceleration of the effective date of the above-referenced Registration Statement
for May 5, 2015 at 4:00 p.m. Eastern time in accordance with Rule 461 of the Securities Act of 1933, as amended.

As representatives of the several underwriters
of the proposed public offering, we hereby respectfully withdraw our request for acceleration of the effectiveness of the above-referenced
Registration Statement set forth in our May 4, 2016 letter.

    Very truly yours,

    JEFFERIES LLC

    By:
    /s/ Ashley Delp Walker

    Name: Ashley Delp Walker
 Title: Managing Director

    BARCLAYS CAPITAL INC.

    By:
    /s/ Victoria Hale

    Name: Victoria Hale
Title: Vice President

cc:  Pankaj Mohan, Oncobiologics, Inc.

    Lawrence Kenyon, Oncobiologics, Inc.

    Stuart M. Cable, Goodwin Procter LLP

    Edwin O’Connor, Goodwin Procter LLP

    Seo Salimi, Goodwin Procter LLP

    Yvan-Claude Pierre, Cooley LLP

    Daniel I. Goldberg, Cooley LLP

    Marianne Sarrazin, Cooley LLP

[Signature
Page to Withdrawal of Underwriters’ Acceleration Request]

SecProbe.io